Table 1.
Patient characteristics.
| IXA (n = 37) | IXA + BEV (n = 39) | |
|---|---|---|
| Age in years, median (range) | 67 (50-88) | 67 (40-78) |
| Race, % (N) | ||
| White | 73% (27) | 80% (31) |
| Black | 22% (8) | 10% (4) |
| Other | 5% (2) | 10%(4) |
| Ethnicity, % (N) | ||
| Hispanic | 8% (3) | 3% (1) |
| Non-Hispanic | 92% (34) | 95% (37) |
| Unknown | 0 | 3% (1) |
| Histology, % (N) | ||
| Serous | 78% (29) | 87% (34) |
| Carcinosarcoma | 6% (2) | 3% (1) |
| Other | 16% (6) | 10% (4) |
| ECOG Performance Status, % (N) | ||
| 0–1 | 84% (31) | 92% (36) |
| 2 | 16% (6) | 8 % (3) |
| Prior Lines of Chemotherapy, % (N) | ||
| ≤3 | 49% (18) | 54% (21) |
| >3 | 51% (19) | 46% (18) |
| Prior PARP inhibitor | ||
| Yes | 38% (14) | 26% (10) |
| No | 62% (23) | 74% (29) |
| Prior Bevacizumab, % (N) | ||
| Yes | 57% (21) | 54% (21) |
| No | 43% (16) | 46% (18) |
| Prior weekly Paclitaxel (for first line treatment or treatment of recurrence), % (N) | ||
| Yes | 27% (10) | 23% (9) |
| No | 73% (27) | 77% (30) |
| Prior receipt of an AURELIA regimen, % (N) | ||
| With Bevacizumab | 16% (6) | 21% (8) |
| weekly paclitaxel | 17% (1) | 50% (4) |
| pegylated liposomal doxorubicin | 33% (2) | 50% (4) |
| topotecan | 17% (1) | 0 |
| >AURELIA regimen | 33% (2) | 0 |
| Without Bevacizumab | 30% (11) | 46% (18) |
| weekly paclitaxel | 9% (1) | 11% (2) |
| pegylated liposomal doxorubicin | 64% (7) | 67% (12) |
| topotecan | 9% (1) | 17% (3) |
| >1 AURELIA regimen | 18% (2) | 5% (1) |
| Platinum refractory/resistant disease, % (N) | ||
| Refractory | 11% (4) | 26% (10) |
| Resistant | 89% (33) | 74% (29) |
| Taxane refractory/resistant disease, % (N) | ||
| Refractory | 27% (10) | 33% (13) |
| Resistant | 24% (9) | 33% (13) |
| Exposed | 49% (18) | 33% (13) |
ECOG Eastern Cooperative Oncology Group.
The study arms were well-balanced across all variables examined with no significant differences between the two groups.